Foundayo, Eli Lilly’s newly launched obesity pill, picked up 1,390 prescriptions in the United States during its launch week, giving investors an early look at demand for the company’s first oral weight-loss treatment. Reuters, citing IQVIA prescription data, reported that the tally covered the week ended April 10, 2026.
The raw figure looked lower than the early launch of Novo Nordisk’s oral Wegovy, which reached 3,071 U.S. prescriptions in its first week. But analysts said the comparison is not straightforward, because Foundayo appears to have had only about two days of tracked market availability during that first reporting window, meaning its initial uptake may have been stronger than the headline number suggests.
Foundayo received FDA approval on April 1, 2026, for adults with obesity, or overweight adults with at least one weight-related medical problem. Lilly said prescriptions were accepted immediately through Lilly Direct, with shipping beginning April 6, followed by broader U.S. pharmacy availability.
The drug is significant because it gives Lilly an entry into the fast-growing oral GLP-1 obesity market, where convenience could become a major competitive advantage over injectable treatments. Lilly says Foundayo is a once-daily oral GLP-1 and can be taken without food or water restrictions, a point the company is emphasizing as it competes with other weight-loss medicines.
Market analysts are now watching whether the strong early pace can hold through the coming weeks. Investor’s Business Daily reported that Wall Street is likely to focus on prescription trends around weeks 8 to 12, when a clearer picture of repeat demand, dose escalation, and patient persistence should emerge.
In short, the launch-week number of 1,390 prescriptions is being read less as a final verdict and more as an early demand signal. For Lilly, the bigger question is whether Foundayo can turn its promising debut into sustained growth in one of the most closely watched drug markets in the U.S.
